Literature DB >> 2263315

Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic lateral sclerosis.

D Troost1, J J Van den Oord, J M Vianney de Jong.   

Abstract

In order to test the hypothesis that the immune system plays a role in the pathogenesis of amyotrophic lateral sclerosis (ALS), the cellular composition of the spinal cord inflammatory infiltrate was analysed in eight cases of sporadic ALS by a panel of monoclonal antibodies. The majority of the many diffusely scattered lymphocytes seen in the anterior and lateral corticospinal tracts and anterior horns belonged to the suppressor/cytotoxicity T-cell subset and were admixed with variable numbers of macrophages. Helper-inducer T-cells were rare and B-cells were conspicuously absent. Compared to controls, ALS specimens exhibited an increase in major histocompatibility complex (MHC) products or human leucocyte antigens (HLA) in the corticospinal tracts and anterior horns. HLA-ABC antigens were expressed in the honeycomb pattern of the glial matrix of the spinal cord, and HLA-DR antigens were strongly expressed by large dendritic cells. In addition, macrophages and endothelial cells were labelled by HLA-DR. These findings suggest that an autoimmune process or infectious agent may play a role in ALS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2263315     DOI: 10.1111/j.1365-2990.1990.tb01276.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  43 in total

1.  From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis.

Authors:  John M Lincecum; Fernando G Vieira; Monica Z Wang; Kenneth Thompson; Gerald S De Zutter; Joshua Kidd; Andrew Moreno; Ricardo Sanchez; Isarelis J Carrion; Beth A Levine; Bashar M Al-Nakhala; Shawn M Sullivan; Alan Gill; Steven Perrin
Journal:  Nat Genet       Date:  2010-03-28       Impact factor: 38.330

Review 2.  Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks.

Authors:  Stefanie M A Willekens; Donatienne Van Weehaeghe; Philip Van Damme; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-08       Impact factor: 9.236

Review 3.  Immune cell regulation of glia during CNS injury and disease.

Authors:  Andrew D Greenhalgh; Sam David; F Chris Bennett
Journal:  Nat Rev Neurosci       Date:  2020-02-10       Impact factor: 34.870

4.  ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity.

Authors:  David R Beers; Weihua Zhao; Jinghong Wang; Xiujun Zhang; Shixiang Wen; Dan Neal; Jason R Thonhoff; Abdullah S Alsuliman; Elizabeth J Shpall; Katy Rezvani; Stanley H Appel
Journal:  JCI Insight       Date:  2017-03-09

Review 5.  Immunological findings in amyotrophic lateral sclerosis.

Authors:  J P Antel; N R Cashman
Journal:  Springer Semin Immunopathol       Date:  1995

Review 6.  Microglia in neurodegenerative disease.

Authors:  V Hugh Perry; James A R Nicoll; Clive Holmes
Journal:  Nat Rev Neurol       Date:  2010-03-16       Impact factor: 42.937

7.  Immunological aspects in amyotrophic lateral sclerosis.

Authors:  Maria Carolina O Rodrigues; Júlio C Voltarelli; Paul R Sanberg; Cesario V Borlongan; Svitlana Garbuzova-Davis
Journal:  Transl Stroke Res       Date:  2012-05-03       Impact factor: 6.829

8.  Inflammatory cells in the peripheral nervous system in motor neuron disease.

Authors:  H Kerkhoff; D Troost; E S Louwerse; M van Dijk; H Veldman; F G Jennekens
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

9.  Expression and localization of prostaglandin transporter in Alzheimer disease brains and age-matched controls.

Authors:  Koyi Choi; Hean Zhuang; Barbara Crain; Sylvain Doré
Journal:  J Neuroimmunol       Date:  2008-03-18       Impact factor: 3.478

Review 10.  Amyotrophic lateral sclerosis.

Authors:  Lokesh C Wijesekera; P Nigel Leigh
Journal:  Orphanet J Rare Dis       Date:  2009-02-03       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.